Johnson & Johnson is dropping a partnership with Genmab centered around a CD38 monoclonal antibody, prompting the latter ...

A head-to-head trial of HexaBody-CD38 versus Darzalex Faspro revealed an overall response rate (ORR) of 55% and 52%, respectively, with Genmab pointing to "deeper responses" with the new drug and a ...

As with other drugs, Darzalex Faspro (daratumumab/hyaluronidase-fihj) can cause side effects, such as upper respiratory tract infection. If you’re not able to ...

Genmab (CSE:GMAB) (NASDAQ:GMAB) announced on Monday, March 10, that Johnson&Johnson (NYSE:JNJ) has chosen not to proceed with the development of GEN3014 (HexaBody-CD38), a next-gen version of their ...

Janssen’s UK pricing chief Jennifer Lee has called for reform of NICE following the company’s successful but drawn-out attempt to get its cancer drug Darzalex to NHS patients. Darzalex will ...

The company's best-known drug, Darzalex (or daratumumab), was developed in partnership with Johnson & Johnson for multiple myeloma. Darzalex is entrenched in multiple myeloma care for several ...

Janssen-Cilag International NV, a Johnson & Johnson company (NYSE:JNJ) announced Friday that an expert panel of the EU drug ...

Darzalex & Darzalex Faspro are indicated for the treatment of multiple myeloma. Walgreens’ three core segments—U.S. pharmacy retailer Walgreens, U.K.-based Boots and specialty unit Shields ...

The company's flagship product, Darzalex, has been a major revenue driver, but the company is now working to diversify its portfolio and prepare for the post-Darzalex era. Want deeper insights ...

Most products closed the year strong with Darzalex royalties leading the way. Epkinly net sales were $78 million, and this was slightly lower than expected due to one-time adjustments in France ...

Its key product, Darzalex, is responsible for a majority of its revenue. Recent strategic actions include leveraging partnerships and investing heavily in research and development to expand its ...

The company held an investor call to discuss the decision, during which it shared initial data from a head-to-head study comparing GEN3014 to Darzalex. While the results suggested potentially deeper ...